Penumbra Inc
NYSE:PEN
Operating Margin
Penumbra Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Penumbra Inc
NYSE:PEN
|
10.4B USD |
7%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
221.6B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138.9B USD |
18%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
134.8B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
108.1B USD |
19%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.6B EUR |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.2B USD |
27%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.3B CNY |
36%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
33B USD |
29%
|
Penumbra Inc
Glance View
In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Penumbra Inc's most recent financial statements, the company has Operating Margin of 7.2%.
You don't have any saved screeners yet